Compare DBX & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBX | CORT |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 9.7B |
| IPO Year | 2018 | 2001 |
| Metric | DBX | CORT |
|---|---|---|
| Price | $34.42 | $114.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $28.14 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 4.2M | 1.2M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.86 | N/A |
| EPS | ★ 0.91 | 0.09 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $0.20 | $26.08 |
| Revenue Next Year | N/A | $26.98 |
| P/E Ratio | ★ $39.51 | $1,228.89 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $21.70 | $28.66 |
| 52 Week High | $35.97 | $122.21 |
| Indicator | DBX | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 61.06 | 64.64 |
| Support Level | $24.64 | $76.41 |
| Resistance Level | N/A | $122.21 |
| Average True Range (ATR) | 1.40 | 5.13 |
| MACD | 0.06 | -0.09 |
| Stochastic Oscillator | 68.04 | 75.23 |
Dropbox provides cloud storage and content collaboration tools, focusing on individuals and small to midsize businesses. Founded in 2007, Dropbox was a pioneer in the file sync and share market. In recent years, the firm has been emphasizing its Dash product, which facilitates AI-powered universal search across unstructured cloud data.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.